Objectives: (1) To develop a clinically useful model with which dermatologists can understand the potential uses of biologic therapy for psoriasis and understand the potential differences among these ...

Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...

Real-world Danish registry data show that biologic drug survival in psoriasis differs between biologic-naive and ...

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Learn about psoriasis treatment costs, from affordable steroids to costly biologics.

Obesity was linked to reduced long-term effectiveness of biologic therapy in patients with severe plaque psoriasis in a study, with dysregulated innate immune responses contributing to treatment ...

Patient advocate Howard Chang’s visit to Boehringer Ingelheim’s biopharmaceutical facility revealed both how biologic ...

The course of COVID-19 in patients with psoriasis was characterized and factors associated with hospitalization were identified in an international case study. The use of biologic agents among ...

Higher BMI, BMR, BSA, and weight correlate with more severe psoriasis and reduced treatment efficacy, particularly with biologic therapies. Personalized dosing strategies may be necessary for biologic ...

Please provide your email address to receive an email when new articles are posted on . There was no significant difference in cardiovascular risks among patients treated with biologics for psoriatic ...

Please provide your email address to receive an email when new articles are posted on . Understanding drug survival is important for clinical prescribing and long-term disease control. Bimekizumab has ...

DelveInsight's Psoriasis Market Insights report includes a comprehensive understanding of current treatment practices, psoriasis emerging drugs, market share of individual therapies, and current and ...